1. Home
  2. CABA vs AIIO Comparison

CABA vs AIIO Comparison

Compare CABA & AIIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.39

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Logo Robo.ai Inc. Class B Ordinary Shares

AIIO

Robo.ai Inc. Class B Ordinary Shares

N/A

Current Price

$0.29

Market Cap

196.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CABA
AIIO
Founded
2017
N/A
Country
United States
United Arab Emirates
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Manufacturing
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
227.2M
196.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CABA
AIIO
Price
$2.39
$0.29
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$13.50
N/A
AVG Volume (30 Days)
2.2M
9.1M
Earning Date
11-10-2025
02-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,742,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.25
52 Week High
$3.67
$3.48

Technical Indicators

Market Signals
Indicator
CABA
AIIO
Relative Strength Index (RSI) 48.61 28.07
Support Level $2.32 $0.46
Resistance Level $2.48 $0.51
Average True Range (ATR) 0.14 0.08
MACD -0.00 -0.01
Stochastic Oscillator 17.50 11.08

Price Performance

Historical Comparison
CABA
AIIO

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

About AIIO Robo.ai Inc. Class B Ordinary Shares

Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.

Share on Social Networks: